Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674739 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
A Phase 3 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT00674739: Completed Phase 3 study, sponsored by Graceway Pharmaceuticals.
NCT00674739 is a Phase 3 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 470 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674739, a Phase 3 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the creams. External genital and perianal warts are caused by the infection of human papillomavirus or HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like small flesh-colored, pink, or red growths on or around the external skin of sex organs or perianal area. The warts may look similar to the small parts of a cauliflower or they may be very tiny and difficult to see. They often appear in clusters of three or four, and may grow and spread rapidly. They usually are not painful, although they may cause mild pain, bleeding, and itching.
Primary Outcome
Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points.
Interventions
- DRUG Imiquimod
- DRUG placebo cream
- DRUG 3.75% imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
What the finished NCT00674739 record still lists
NCT00674739 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 3 interventions - of which Imiquimod is the first listed.
NCT00674739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00674739 about?
NCT00674739 is a clinical study titled "Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts". The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the ...
What is the current status of trial NCT00674739?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2008-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00674739?
The interventions under investigation include: Imiquimod (DRUG), placebo cream (DRUG), 3.75% imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00674739?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00674739's enrollment target sits among peer trials
470 813th of 2000 higher than 1,186 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia